Date Filer Title Filing Type Shares Traded Price Total Held
Feb 17, 2023
Holmlin R. Erik
Director, President and CEO
Trans History: 32
 Director, President and CEO Form 4 Other acquisition or disposition -- -- 5,025
Feb 15, 2023
Chaubey Alka
Chief Medical Officer
Trans History: 15
 Chief Medical Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 120,000 -- 124,794
Feb 15, 2023
Chaubey Alka
Chief Medical Officer
Trans History: 15
 Chief Medical Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 560,000 -- 560,000
Feb 15, 2023
Holmlin R. Erik
Director, President and CEO
Trans History: 32
 Director, President and CEO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 300,000 -- 841,615
Feb 15, 2023
Holmlin R. Erik
Director, President and CEO
Trans History: 32
 Director, President and CEO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 1,400,000 -- 1,400,000
Feb 15, 2023
OLDAKOWSKI MARK
Chief Operating Officer
Trans History: 22
 Chief Operating Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 120,000 -- 339,338
Feb 15, 2023
OLDAKOWSKI MARK
Chief Operating Officer
Trans History: 22
 Chief Operating Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 560,000 -- 560,000
Feb 15, 2023
Stewart Christopher P.
Chief Financial Officer
Trans History: 14
 Chief Financial Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 105,000 -- 231,373
Feb 15, 2023
Stewart Christopher P.
Chief Financial Officer
Trans History: 14
 Chief Financial Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 490,000 -- 490,000
Aug 15, 2022
Linney Yvonne
Director
Trans History: 12
 Director Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 20,000 $0.38 20,000

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.